Clinical trial
Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients…
NCT00343447 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Withdrawn
Key facts
| NCT number | NCT00343447 |
|---|---|
| Title | Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia |
| Official title | Phase II Randomized Trial of Early Versus Late Vaccination in Patients With High Risk CLL |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | autologous tumor cell vaccine, rituximab, cyclophosphamide |
| Enrollment | 0 |
| Start date | Aug 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Jun 23, 2006 |
| Last update posted | May 3, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: